Genprex raises $6.5M in registered direct offering with warrants; existing warrants amended

Genprex, Inc.

Gross proceeds $6.5M; net estimated ~$5.8M after placement agent fees and expenses.
Offers 1,542,112 shares or pre-funded warrants plus 1,542,112 warrants at $4.215 per unit.
Warrants exercisable at $4.09 per share, expire 5 years from issuance.
Amends existing warrants for 194,248 shares from $44/$35.40 to $4.09 exercise price; extends expiration to 5 years from closing.
H.C. Wainwright acts as placement agent; receives 7% cash fee and 92,527 placement agent warrants.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Genprex, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.8 million (effective 2024-03-19).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: approximately $5.8 million
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor

View on SEC.gov

547 material agreements filed in the last 30 days. Browse all material agreements →

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-008592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.